NCT01277991 - A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

Treatment A

Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)

DRUG

Treatment B

Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)

DRUG

Treatment B

Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)

DRUG

Treatment A

Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)

Trial Locations (1)

Pfizer Investigational Site, Singapore